SE509991C2 - Biodegradable tissue enhancement - Google Patents
Biodegradable tissue enhancementInfo
- Publication number
- SE509991C2 SE509991C2 SE9202208A SE9202208A SE509991C2 SE 509991 C2 SE509991 C2 SE 509991C2 SE 9202208 A SE9202208 A SE 9202208A SE 9202208 A SE9202208 A SE 9202208A SE 509991 C2 SE509991 C2 SE 509991C2
- Authority
- SE
- Sweden
- Prior art keywords
- polymer
- poly
- use according
- injection
- tissue
- Prior art date
Links
- 238000002347 injection Methods 0.000 claims abstract description 12
- 239000007924 injection Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 229920000642 polymer Polymers 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 230000003014 reinforcing effect Effects 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 2
- 229920001397 Poly-beta-hydroxybutyrate Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 229920000117 poly(dioxanone) Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 3
- 239000004621 biodegradable polymer Substances 0.000 claims 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 229920006237 degradable polymer Polymers 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 210000005070 sphincter Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002787 reinforcement Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000001260 vocal cord Anatomy 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- -1 poly-6-valerolactone Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
509 991 2 vävnad. Enligt uppfinningen sprutas polymeren in i vävnaden och när den har stelnat blir den ett av insprutningen styrt nätverk vilket håller samman de strukturer som önskas förstärkas. Med andra ord skapas en aktiv förstärkning med förankringspunkter i vävnaden. Under läkningen utövar de även en viss retning, varvid kompositionens försvinnande ersätts med bindväv. 509 991 2 tissue. According to the invention, the polymer is injected into the tissue and when it has solidified, it becomes a network controlled by the injection, which holds together the structures which it is desired to strengthen. In other words, an active reinforcement is created with anchoring points in the tissue. During healing, they also exert a certain irritation, whereby the disappearance of the composition is replaced by connective tissue.
Polymeren som används i uppfinningen kan vara polyglykolider och sampolymerisat därav, polylaktider' och sampolymerisat därav, poly-ß-hydroxybutyrat och.sampolymerisat:därav, poly-p-dioxanon, poly-6-valerolakton,poly-E-kaprolakton,metylmetakrylat-N-vinyl pyrrolidon sampolymerisat, polyesteramider, polyestrar av oxalsyra, polydihydropyraner, poly-alkyl-2-cyanoakrylater, polyuretaner, polyvinylaklohol, polypeptider, poly-ß-malinsyra, poly-B-alkanoinsyror och alginater av olika former. Man.kan också använda en kombination av en eller flera av dessa polymerer.The polymer used in the invention may be polyglycolides and copolymers thereof, polylactides and copolymers thereof, poly-β-hydroxybutyrate and copolymers: thereof, poly-p-dioxanone, poly-6-valerolactone, poly-ε-caprolactone, methyl methacrylate-N -vinyl pyrrolidone copolymers, polyesteramides, polyesters of oxalic acid, polydihydropyrans, polyalkyl-2-cyanoacrylates, polyurethanes, polyvinyl alcohol, polypeptides, poly-β-malic acid, poly-β-alkanoic acids and alginates of various forms. It is also possible to use a combination of one or more of these polymers.
Polymeren är flytande vid applicering och är lämpligen löst i ett lösningsmedel såsom aceton. Det är dock även tänkbart att värma upp polymeren till < 42°, vilket är den maximala temperatur som vävnaden tål. När alginater används tvärbinds dessa på plats i vävnaden med hjälp av 2-värda joner.The polymer is liquid upon application and is suitably dissolved in a solvent such as acetone. However, it is also conceivable to heat the polymer to <42 °, which is the maximum temperature that the fabric can withstand. When alginates are used, they are cross-linked in place in the tissue using 2-valent ions.
Enligt uppfinningen är det också möjligt att kombinera den förstärkande effekten med läkemedel, såsom t ex. tillväxtgynnande medel och antiobiotika.According to the invention, it is also possible to combine the reinforcing effect with drugs, such as e.g. growth promoters and antibiotics.
Vidare kan polymeren valfritt vara försedd med monofilament, t ex små bitar av vicrylsutur för att förstärka armeringseffek- ten.Furthermore, the polymer may optionally be provided with monofilaments, for example small pieces of vicryl suture to enhance the reinforcing effect.
Ytterligare en variant av uppfinningen är innefatta de redan kända utfyllande materialen, såsom kollagen, glukosaminoglukaner m.fl, tillsammans med polymererna enligt uppfinningen.Another variant of the invention is to comprise the already known complementary materials, such as collagen, glucosaminoglucans and others, together with the polymers according to the invention.
Uppfinningens generella utförande kan beskrivas enligt följande: 509 991 3 1. En kanyl eller annat lämpligt instrument förs in i vävnaden där förstärkningen önskas. 2. Med hjälp av instrumentet, som kan *vara skärande eller trubbigt, skapas hålrum i vävnaden. 3. Instrumentet avlägsnas. 4. En kanyl eller kateter fylld med flytande polymert material förs in i hàlrummet(en), varefter det polymera materialet sprutas ut däri. 5. Kanylen avlägsnas och det polymera materialet får stelna.The general embodiment of the invention can be described as follows: 509 991 3 1. A cannula or other suitable instrument is inserted into the tissue where the reinforcement is desired. With the help of the instrument, which can * be cutting or blunt, cavities are created in the tissue. 3. The instrument is removed. A cannula or catheter filled with liquid polymeric material is inserted into the cavity (s), after which the polymeric material is ejected therein. 5. The cannula is removed and the polymeric material is allowed to solidify.
Uppfinningen kommer nu att beskrivas närmare nedan i anslutning till några exempel.The invention will now be described in more detail below in connection with some examples.
Exempel 1: Sammanfoqninq av menisk En spricka i en menisk kan sammanfogas enligt uppfinningen på följande sätt: En skarp, skärande nål förs under artropisk kontroll in i sprickan sà att denna penetreras, varefter nålen avlägsnas. En massa innefattande 30% polylaktid i aceton armerad med 2 mm bitar av monofilament vicrylsutur förs in i sprickan med hjälp av en kanylförsedd kateter. Massan trycks ut så att en klump bildas i början och slutet av sprickan under det att kanylen sakta àterdras. Under de första 5 till 10 minuterna efter appliceringen trycks sprickan ihop med ett trubbigt instrument, t ex hylsan till nàlkatetern.Example 1: Joining the meniscus A crack in a meniscus can be joined according to the invention in the following way: A sharp, cutting needle is inserted under arthropic control into the crack so that it penetrates, after which the needle is removed. A mass comprising 30% polylactide in acetone reinforced with 2 mm pieces of monofilament vicrylsuture is inserted into the crack by means of a cannulated catheter. The mass is pressed out so that a lump forms at the beginning and end of the crack while the cannula is slowly retracted. For the first 5 to 10 minutes after application, the crack is compressed with a blunt instrument, such as the sleeve of the needle catheter.
Exempel 2: Refluxkorrigering En vanlig defekt hos barn upp till 10 års ålder är ofullständig funktion hos uretärens inlopp i urinblàsan. Den normala backven- tilfunktionen har förlorats och urin strömmar åter från blàsan till urinledaren. Detta leder till att dessa barn ofta får urinledarinfektioner med hotad njurfunktion som följd. För att skydda njurnarna får dessa barn ofta äta antibiotika i åratal.Example 2: Reflux correction A common defect in children up to the age of 10 is incomplete function of the ureter's inlet into the bladder. The normal back valve function has been lost and urine flows back from the bladder to the ureter. This leads to these children often getting urinary tract infections with threatened kidney function as a result. To protect the kidneys, these children often have to eat antibiotics for years.
Om detta inte hjälper vidtages operation. Det är ett kostsamt och 509 991 4 relativt komplicerat ingrepp med lång utläkning och stort besvär för patienten.If this does not help, surgery is performed. It is a costly and relatively complicated procedure with long healing and great inconvenience for the patient.
Med utgångspunkt från att defekten kan ha sitt ursprung i en vävnadsförsvagning i blåsväggen utfördes med cystoskopisk teknik en vävnadsförstärkning genom att en nål infördes i blåsväggen under slemhinnan.Assuming that the defect may have originated in a tissue weakening in the bladder wall, a tissue augmentation was performed with cystoscopic technique by inserting a needle into the bladder wall under the mucosa.
Denna vävnadsförstärkning utfördes genom att ca 1 ml 20% polymer laktidlösning sprutades in under blåsans slemhinna. När lösningen stelnat utgjorde den uppkomna plattanmett bra mothåll mot blàsans inre tryck så att återläckaget förhindrades. Laktidpolymeren bryts nu ned (6 månader efter injektion) och lämnar en bindvävs- svål efter sig vilken förefaller ge ett tillfredsställande mothåll för en bibehållen backventilfunktion.This tissue augmentation was performed by injecting approximately 1 ml of 20% polymeric lactide solution under the bladder mucosa. When the solution solidified, the resulting plate met with good resistance to the internal pressure of the bladder so that the leakage was prevented. The lactide polymer is now degraded (6 months after injection) and leaves a connective tissue swelling which appears to provide a satisfactory resistance for a maintained non-return valve function.
Exempel 3: Förstärkning av sfinkterfunktion Kroppen är utrustad med avständningsanordningar av sfinktertyp i framförallt mag-tarmkanalen och i urinblåsans avtappningsrör (uretra). Eftersom buken utsätts för övertryck i samband med kroppsansträngning eller nysningar/hostningar måste dessa öppningar kunna stängas effektivt. Därför har magmunnen en "ringmuskel" som snabbt och effektivt kan stänga in magsäckens innehåll. Även magsäckens nedre del sluts med en ringmuskel så att födan kan portioneras ut i tarmkanalen på ett styrt sätt.Example 3: Reinforcement of sphincter function The body is equipped with sphincter-type sensing devices in the gastrointestinal tract in particular and in the bladder drainage tube (urethra). As the abdomen is exposed to overpressure in connection with physical exertion or sneezing / coughing, these openings must be able to be closed effectively. Therefore, the stomach has a "sphincter" that can quickly and efficiently close the contents of the stomach. The lower part of the stomach is also closed with an sphincter so that the food can be portioned out in the intestinal tract in a controlled manner.
Slutligen har tarmens avslutning en dubbel sfinkter för att säkert hålla avföringen under kontroll. I samtliga dessa fall, och i fler här ej nämnda, kan den ringslutande funktionen delvis tappas eller förslappas så att läckage uppstår. Dessa är mycket generande och för många patienter utgör de ett stort problem. Å andra sidan är tillstånden inte livshotande och ofta associerde med hög ålder varför sjukvården inte sätter in tunga resurser för att åtgärda dessa. En förenklad metod skulle tveklöst vara mycket välkommen för såväl patienter som läkare. 509 991 5 I en majoritet av sfinkterfunktionsstörningarna föreligger inget absolut hinder för att full funktion skulle kunna etableras. I de flesta fall räcker sannolikt en vävnadsförstärkning för att ge det stöd som restfunktionen behöver för en fullgod funktion.Finally, the end of the bowel has a double sphincter to safely keep the stool under control. In all these cases, and in more not mentioned here, the ring-closing function can be partially lost or slackened so that leakage occurs. These are very embarrassing and for many patients they are a major problem. On the other hand, the conditions are not life-threatening and are often associated with old age, which is why healthcare does not invest heavy resources to remedy these. A simplified method would undoubtedly be very welcome for both patients and doctors. 509 991 5 In a majority of sphincter dysfunctions, there is no absolute obstacle to full function being established. In most cases, a tissue augmentation is probably sufficient to provide the support that the residual function needs for a proper function.
En 55-årig kvinna sökte för urinavgång i samband med fysisk ansträngning. Problemet hade tilltagit med åren. Efter under- sökning med fiberoptisk teknik samt ultraljud hade konstaterats att sfinktern partiellt försvagats. Efter injektion av S ml 20% polymer laktidlösning under slemhinnan så att en cirkulär öppning återskapats var kvinnan besvärsfri 3 månader efter behandlingen.A 55-year-old woman applied for urination in connection with physical exertion. The problem had increased over the years. After examination with fiber optic technology and ultrasound, it had been established that the sphincter had been partially weakened. After injection of 5 ml of 20% polymeric lactide solution under the mucosa so that a circular opening was recreated, the woman was trouble-free for 3 months after treatment.
Motsvarande behandlingar av andra ringmuskelslutare är uppenbara för fackmannen på teknikområdet.Corresponding treatments of other sphincter shutters are obvious to those skilled in the art.
Exempel 4: Stämbandsatrofi Ett specialfall utgjorde en patient vars röst nästan förlorats efter en strålbehandling av halsregionen. Efter undersökning konstaterades att en den av stämbanden atrofierat och förskjutits i höjdled. Följden hade blivit en närmast väsande röst vilket besvärade patienten i dennes yrkesroll. Under fiberoptisk kontroll gavs en injektion i stämbandets försvagade del med 2 ml 20% laktidpolymerlösning. En för patienten tillfredsställande röstfunktion var stabiliserad efter 3 månader.Example 4: Vocal atrophy A special case was a patient whose voice was almost lost after a radiotherapy of the neck region. After examination, it was found that one of the vocal cords had been atrophied and displaced in height. The result had been an almost hissing voice, which bothered the patient in his professional role. Under fiber optic control, an injection was given in the weakened part of the vocal cord with 2 ml of 20% lactide polymer solution. A patient-satisfying voice function was stabilized after 3 months.
I samtliga ovan angivna Exempel är det möjligt att tillsätta tillväxtgynnande medel, antibiotika mfl läkemedel efter behov.In all the above examples, it is possible to add growth-promoting agents, antibiotics, etc. drugs as needed.
Ur ovanstående framgår att den här beskrivna vävnadsförstärk- ningen utförd med injektionsteknik under fiberoptisk kontroll är en snabb, billig och enkel metod som sannolikt inte leder till ett permanent tillstànd men som under något till några år återskapar en förlorad funktion. Eftersom metoden är enkel kan behandlingen lätt upprepas vid behov.From the above it appears that the tissue reinforcement described here performed with injection technique under fiber optic control is a fast, cheap and simple method which probably does not lead to a permanent condition but which for a few to a few years recreates a lost function. Because the method is simple, the treatment can be easily repeated if necessary.
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9202208A SE509991C2 (en) | 1992-07-20 | 1992-07-20 | Biodegradable tissue enhancement |
| PCT/SE1993/000586 WO1994002184A1 (en) | 1992-07-20 | 1993-06-28 | Tissue augmentation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9202208A SE509991C2 (en) | 1992-07-20 | 1992-07-20 | Biodegradable tissue enhancement |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9202208D0 SE9202208D0 (en) | 1992-07-20 |
| SE9202208L SE9202208L (en) | 1994-01-21 |
| SE509991C2 true SE509991C2 (en) | 1999-03-29 |
Family
ID=20386819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9202208A SE509991C2 (en) | 1992-07-20 | 1992-07-20 | Biodegradable tissue enhancement |
Country Status (2)
| Country | Link |
|---|---|
| SE (1) | SE509991C2 (en) |
| WO (1) | WO1994002184A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391167A (en) * | 1992-09-01 | 1995-02-21 | Ortho-Motion, Inc. | Articulating external fixation device |
| WO1994021299A1 (en) * | 1993-03-19 | 1994-09-29 | Medinvent | A composition and a method for tissue augmentation |
| JP3220331B2 (en) * | 1993-07-20 | 2001-10-22 | エチコン・インコーポレーテツド | Absorbable liquid copolymers for parenteral administration |
| US6335383B1 (en) | 1994-10-18 | 2002-01-01 | Ethicon, Inc. | Microdispersions for coating surgical devices |
| US5599852A (en) * | 1994-10-18 | 1997-02-04 | Ethicon, Inc. | Injectable microdispersions for soft tissue repair and augmentation |
| AU706434B2 (en) * | 1994-10-18 | 1999-06-17 | Ethicon Inc. | Injectable liquid copolymers for soft tissue repair and augmentation |
| FR2764514B1 (en) | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | IMPLANT INJECTED IN SUBCUTANEOUS OR INTRADERMAL WITH CONTROLLED BIORESORBABILITY FOR REPAIR OR PLASTIC SURGERY AND AESTHETIC DERMATOLOGY |
| PT1163019E (en) | 1999-03-25 | 2007-12-06 | Metabolix Inc | Medical devices and applications of polyhydroxyalkanoate polymers |
| ATE323516T1 (en) * | 1999-09-14 | 2006-05-15 | Tepha Inc | POLYHYDROXYALCANONE COMPOSITION FOR REPAIR, CONSTRUCTION AND AS A VISCOSITY ADDITIVE OF SOFT TISSUE |
| US7025980B1 (en) | 1999-09-14 | 2006-04-11 | Tepha, Inc. | Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation |
| US6423332B1 (en) | 2000-05-26 | 2002-07-23 | Ethicon, Inc. | Method and composition for deforming soft tissues |
| FR2850282B1 (en) | 2003-01-27 | 2007-04-06 | Jerome Asius | INJECTABLE IMPLANT BASED ON CERAMIC FOR THE FILLING OF WRINKLES, CUTANEOUS DEPRESSIONS AND SCARS, AND ITS PREPARATION |
| JP2007525601A (en) | 2003-05-08 | 2007-09-06 | テファ， インコーポレイテッド | Polyhydroxyalkanoate medical fabric and medical fiber |
| ES2395464T3 (en) | 2004-08-03 | 2013-02-12 | Tepha, Inc. | Non-curly polyhydroxyalkanoate sutures |
| US10500303B2 (en) | 2014-08-15 | 2019-12-10 | Tepha, Inc. | Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof |
| WO2016094669A1 (en) | 2014-12-11 | 2016-06-16 | Tepha, Inc. | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof |
| US10626521B2 (en) | 2014-12-11 | 2020-04-21 | Tepha, Inc. | Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595713A (en) * | 1985-01-22 | 1986-06-17 | Hexcel Corporation | Medical putty for tissue augmentation |
| US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| US5077049A (en) * | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
| US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
-
1992
- 1992-07-20 SE SE9202208A patent/SE509991C2/en not_active IP Right Cessation
-
1993
- 1993-06-28 WO PCT/SE1993/000586 patent/WO1994002184A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE9202208D0 (en) | 1992-07-20 |
| SE9202208L (en) | 1994-01-21 |
| WO1994002184A1 (en) | 1994-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE509991C2 (en) | Biodegradable tissue enhancement | |
| DE60009020T2 (en) | Removable stent for body vessels | |
| EP0357846B1 (en) | Apparatus for achieving urinary continence | |
| EP0436667B1 (en) | Biodegradable in-situ forming implants | |
| US6979317B2 (en) | Device for delivering non-biodegradable bulking composition to a urological site | |
| DE69527848T2 (en) | DEVICES FOR PROMOTING TISSUE GROWTH | |
| US20090304773A1 (en) | Surgical adhesive and uses therefore | |
| JPS6324938A (en) | Assembly for embedding urinary prosthetic instrument for treating incontinent under skin | |
| JPH10507392A (en) | Medical prosthesis to prevent gastric reflux in the esophagus | |
| JP4405003B2 (en) | Porous anti-adhesive material | |
| US7094260B2 (en) | Biodegradable common bile duct stent and the method for preparing thereof | |
| CA2827956A1 (en) | Drug releasing pelvic treatment system and method | |
| JP2002537910A (en) | Implant positioning system and method | |
| CN104473706B (en) | Biodegradable composite type tubular urethral stent and preparation method | |
| AU612692B2 (en) | Apparatus and methods for achieving urinary continence | |
| Uchibori et al. | Use of a pedicled omental flap to reduce inflammation and vascularize an abdominal wall patch | |
| Greenstein et al. | Evaluation of polylactic acid-carbon mesh for repair of ventral herniorrhaphy | |
| Kock et al. | Continent colostomy: An experimental study in dogs | |
| Hensle et al. | Pyeloplasty (Anderson‐Hynes) | |
| CN204618494U (en) | A kind of degradable composite tubular urethra rack | |
| Kohri et al. | Long-term results and curative mechanisms of vesicoureteral reflux by endoscopic injection of blood | |
| CN219896547U (en) | Anti-inflammatory anti-calculus acellular matrix composite membrane | |
| AU644581B2 (en) | Biodegradable in-situ forming implants | |
| WO2024194873A1 (en) | Medical device for treating anorectal disorders | |
| CN118161672A (en) | Anti-deformation acellular matrix composite membrane and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |